HTX-011
Drug400 mg
NCT Number: NCT06109415
This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing Total Shoulder Arthroplasty (TSA) (Cohort 1).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
400 mg
100 mg
400 mg
1 g
Applicator for instillation
Time frame: Through Day 15
Time frame: Through 144 hours
Time frame: Through 144 hours
Time frame: Through 144 hours
Time frame: Through 144 hours
Time frame: Through 144 hours
Heron Therapeutics
Industry
A Phase 4, Randomized, Blinded, Active-Controlled Study of HTX-011 in Subjects Undergoing Total Shoulder Arthroplasty (TSA)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07359469
Multimodal Analgesia, Neurologic Manifestations
Girona, Spain
View Trial DetailsNCT06133933
Neurologic Manifestations, Opioid Use
Camden, New Jersey, United States
View Trial DetailsNCT06860100
Cardiovascular Diseases, Digestive System Diseases
Van, Tuşba, Turkey (Türkiye)
View Trial DetailsNCT07724678
Agnosia, Breast Cancer
Altındağ, Ankara, Turkey (Türkiye)
View Trial Details